EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis

Ki Ju Cho iD, Ji Hyun Seo, Hayeong Kwon iD, Seung-Jun Lee iD, Young-Sool Hah iD, Jung Je Park iD

Cancers · 27.06.2026 · 18 (13) · 2093

DOI: 10.3390/cancers18132093 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.06.2026. Verfasst von Ki Ju Cho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Myongji Hospital, Hanyang University Medical Center, 55 Hwasu-ro 14 beon-gil, Goyang 10475, Republic of Korea. Die Arbeit nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Gyeongsang National University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid cancer (TC) is the most common endocrine malignancy, with incidence increasing worldwide. Although most differentiated TCs have a favorable prognosis, radioiodine (RAI)-refractory differentiated thyroid cancer (DTC), BRAF inhibitor-resistant papillary thyroid cancer, and anaplastic thyroid cancer (ATC) remain major areas of unmet clinical need. The sirtuin (SIRT) family of NAD+-dependent enzymes has emerged as a multifaceted regulator of TC biology, with isoform-specific dichotomous roles: SIRT1, SIRT6, and SIRT7 act as tumor promoters through engagement of BRAF/MAPK, PI3K/AKT, epithelial–mesenchymal transition (EMT), and Hippo pathways, while SIRT3 and SIRT4 function as tumor suppressors via mitochondrial metabolic regulation. This review synthesizes recent developments that expand the therapeutic landscape: (i) the recognition that SIRT7 functions as a desuccinylase with preclinically identified oncogenic substrates, modifying KIF23 in ATC and LATS1 in PTC; (ii) the emerging roles of isoform-specific SIRT axes, including the NAMPT–SIRT1–PD-L1 axis, SIRT6-associated regulatory T-cell biology, and SIRT2 as a T-cell metabolic checkpoint, as determinants of immune microenvironment state and potential modulators of immune checkpoint inhibitor response; and (iii) the SIRT6–nuclear receptor coactivator 4 (NCOA4) ferritinophagy axis as a supported ferroptosis vulnerability in ATC, with potential but still hypothesis-generating relevance to dedifferentiated and RAI-refractory DTC. Importantly, the therapeutic logic for SIRT6 is disease-state-specific rather than contradictory: SIRT6 inhibition is rationalized in BRAF-driven aggressive PTC and DTC contexts where SIRT6 supports MAPK signaling, EMT, and ferroptosis resistance, whereas in SIRT6-high ATC, the same enzyme’s NCOA4-dependent ferritinophagy activity may instead be exploited to enhance ferroptosis sensitivity. We review the current SIRT modulator pharmacological toolkit—including EX-527, OSS_128167, and emerging SIRT7-selective inhibitors—and identify the substantial clinical translation gap, with no SIRT-targeted clinical trial yet conducted in TC, despite strong preclinical rationale. We outline biomarker-stratified combination strategies with BRAF/MEK inhibitors, multikinase inhibitors, immune checkpoint inhibitors, and ferroptosis inducers, prioritizing biomarker-driven preclinical validation and, where supported by efficacy and safety data, subsequent early-phase evaluation in BRAF V600E-mutant and SIRT6-high thyroid cancer. Sirtuins thus represent a mechanistically promising and potentially biomarker-stratifiable therapeutic hypothesis for difficult-to-treat thyroid cancer; however, clinical translation remains at an early stage and requires validated biomarkers, isoform-selective compounds, and disease-specific in vivo evidence.

Schlagwörter

Stichwörter der Autor:innen

BRAF V600ESIRT6SIRT7anaplastic thyroid cancerdesuccinylationferroptosisradioiodine refractorinesssirtuinthyroid cancertumor immunity

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Myongji Hospital, Hanyang University Medical Center, 55 Hwasu-ro 14 beon-gil, Goyang 10475, Republic of Korea.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University College of Medicine, 79 Gangnam-ro, Jinju 52725, Republic of Korea.
  • Institute of Medical Science, Gyeongsang National University College of Medicine, 816-15 Jinju-daero, Jinju 52727, Republic of Korea.
  • Department of Pediatrics, Gyeongsang National University College of Medicine, 816-15 Jinju-daero, Jinju 52725, Republic of Korea.
  • Department of Surgery, Gyeongsang National University College of Medicine, 816-15 Jinju-daero, Jinju 52725, Republic of Korea.
  • Biomedical Research Institute, Gyeongsang National University Hospital, 79 Gangnam-ro, Jinju 52727, Republic of Korea.

ORCID-Profile: Ki Ju Cho, Hayeong Kwon, Seung-Jun Lee, Young-Sool Hah, Jung Je Park

Förderung

  • National Research Foundation of Korea
  • Gyeongsang National University Hospital

Zitieren

APA

Cho, K. J., Seo, J. H., Kwon, H., Lee, S. J., Hah, Y. S., & Park, J. J. (2026). Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis. Cancers, 18(13), 2093. https://doi.org/10.3390/cancers18132093

Vancouver

Cho KJ, Seo JH, Kwon H, Lee SJ, Hah YS, Park JJ. Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis. Cancers. 2026;18(13):2093. doi:10.3390/cancers18132093

BibTeX
@article{Cho2026,
  author = {Cho, Ki Ju and Seo, Ji Hyun and Kwon, Hayeong and Lee, Seung-Jun and Hah, Young-Sool and Park, Jung Je},
  title = {Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {13},
  pages = {2093},
  doi = {10.3390/cancers18132093}
}
Kostenlos starten →